What Folligon Treats: Main Uses and Benefits

Folligon, which contains the active substance Equine Serum Gonadotrophin (eCG), is a veterinary medicinal product used across domains where additional symptomatic support is needed to enhance reproductive efficiency in livestock. This medicine is considered relevant for conditions where functional stability becomes affected in the reproductive system.

Folligon assists with managing symptoms associated with acute or episodic changes, particularly those involving irregular manifestation. The primary therapeutic goals involve contexts such as the induction and synchronization of oestrus and ovulation, helping with increased ovulation rate/litter size, and use in superovulation scenarios. It is commonly used to help with symptom clusters that may become intense or disruptive and interfere with daily comfort. The overall goal is to provide supportive relief when symptoms interfere with routine activities.

“It is applied in situations involving certain distressing symptoms related to systemic imbalance.”

Quick Fact: May assist with symptoms related to physical discomfort during periods of heightened physiological activity.

Folligon (Pregnant Mare Serum Gonadotrophin, PMSG) is a Veterinary Medicinal Product that is Not For Human Use. Regulatory documents strictly define its use for specific animal populations and clinical states.

Official Eligibility and Contraindications

All use is restricted to the officially listed target species and must be administered under veterinary care, as Folligon can influence fertility in humans if accidentally self-injected.

Interactions with other medicines and products

The official regulatory documentation for Folligon, which contains Pregnant Mare Serum Gonadotrophin (PMSG), defines its entire interaction profile based on the explicit absence of known pharmacological interactions.

Official Pharmacological Interaction Profile

Government regulatory authorities explicitly state that no known interactions with other medicinal products are documented for Folligon. This means the product label contains no information on:

• Contraindicated combinations: No specific medicines or substance combinations are prohibited due to a known interaction risk.
• Metabolic or Transporter Interactions: No effects on drug-metabolizing enzymes (like CYP) or drug transporters (like P-gp) are documented.
• Pharmacodynamic Interactions: No known additive or synergistic effects with other substances are listed.
• Exposure Modification: No co-administered products are officially known to increase or decrease Folligon’s systemic exposure.
• Food, Alcohol, or Supplements: No interactions with food, alcohol, or herbal products are documented.

Procedural Interaction Constraints

The only official constraint related to co-administration is a physical and chemical incompatibility rule.

Folligon must not be mixed with any veterinary medicinal product other than the specific solvent supplied for its reconstitution prior to administration. This is a procedural restriction and not a pharmacological drug-drug interaction.

Folligon acts as a modulator of the primary catabolic pathway. The drug selectively binds to the RANKL receptor on osteoclast precursors, leading to the inhibition of the NF-κB signaling cascade. This interaction directly inhibits osteoclast differentiation and activation, which subsequently downregulates the transcription of specific pro-resorptive enzymes and reduces C-terminal telopeptide (CTx) production. The net effect is a reduction in bone resorption activity mediated by a specific molecular antagonist binding to the cell surface receptor. This mechanism disrupts the signaling required for mature osteoclast function, focusing its effect at the cellular level to modify the natural process of bone turnover.

How Folligon is Used: Official Administration Guidelines

Folligon, which contains Pregnant Mare Serum Gonadotrophin (PMSG), is officially administered as a standardized injectable solution within structured reproductive management programs for livestock. Its use is defined by established protocols covering precise routes, preparation, and single-dose regimens.

Administration and Preparation

The product is supplied as a lyophilisate (freeze-dried powder) that requires reconstitution with a sterile diluent just prior to use. Once prepared, the solution is administered via injection. The approved routes typically include intramuscular (IM) injection, which is common for cattle and sheep, and subcutaneous (SC) injection, an approved route for swine.

Dosing and Schedule

Folligon is an intermittent, single-dose treatment where the dose, expressed in International Units (IU) of PMSG, is strictly dependent on the target animal species and the desired reproductive goal. The drug is not used in a long-term, daily regimen.

Standard protocols require the injection to be timed precisely, usually administered concurrently with the end of a preparatory progestagen treatment in the synchronization protocol. Furthermore, dosing for superovulation and increased fertility may require adaptation based on breed and season.

Research Evidence / Overview of Studies for Folligon

Folligon (PMSG) was evaluated in studies exploring its use in managing reproduction in farm animals. The research focuses on how this veterinary product was evaluated in controlled settings to monitor the timing of reproductive cycles and to observe changes in the number of eggs produced. The evidence gathered helps to contextualize how this medicine was observed in large animal populations, though results often describe group patterns, not personal outcomes for individual animals.

Evidence for Use in Inducing and Synchronizing Oestrus

Research primarily involved Randomized Controlled Trials (RCTs) and Clinical Efficacy Field Studies used to examine protocols for managing reproductive timing. These designs research explored different protocols for managing the heat period (oestrus) in female livestock, including cows, heifers, ewes, and sows. Studies monitored the Oestrus Response Rate and the time to Onset of Oestrus to see how closely the cycles were measured for grouping.

The findings describe patterns observed in the studies where Folligon, when used in combination with other hormone treatments, was associated with a measured synchronization response in the observed groups. Studies reported that the measured Oestrus Response Rate was observed in some studies to vary significantly based on factors like the animal’s breed and current reproductive state. What remains uncertain is the full characterization of the synchronization outcome for animals experiencing persistent anoestrus without improvements in nutrition or environment, as findings were mixed in these subgroups.

Evidence for Use in Superovulation

Research into superovulation, which involves protocols designed to elevate the number of ovulations to produce multiple eggs for embryo transfer, primarily used Controlled Field and Laboratory Studies. These studies explored outcomes related to systemic or functional imbalance, specifically looking at the Number of Ovulations and the resulting Number of Collectible Embryos in female donor cattle. Studies reported measurements of a change in the ovulation rate following administration as part of an established regimen. The evidence describes that the measured response was observed in some studies to be highly subject to individual variation among the donor animals. What remains uncertain is how to consistently elicit the desired ovarian response, as the dose can vary widely based on the animal's age and history.

Key Studies & References

1. Folligon PMSG Injection Overview (Product Information Document containing indications and study summaries)
2. Influence of PMSG on Superstimulation and Embryo Development Following Somatic Cell Nuclear Transfer in Holstein Cows in the United Arab Emirates
3. Review on Estrus Synchronization and Its Application in Cattle (Contextual Review for Synchronization Protocols)

Common questions about Folligon (FAQ)

Q: What are the most common side effects of Folligon?

According to official product information, there is no side effect of Folligon classified with a 'common' or 'very common' frequency. Allergic reactions, including anaphylactic shock, are classified as rare (affecting 1 to 10 animals in 10,000 treated). Local irritation at the injection site may occur, but its frequency is not formally classified in regulatory documents.

Q: What specific diluent is Folligon mixed with?

Folligon (the freeze-dried powder) must be reconstituted, or mixed, with the specific solvent for reconstitution that is supplied with the product. The official product information specifies that the product must not be mixed with any other veterinary medicinal product prior to administration.

Q: Is Folligon the same as Equine Chorionic Gonadotropin (eCG)?

Yes, Folligon's active ingredient, Pregnant Mare Serum Gonadotrophin (PMSG), is also known as Equine Chorionic Gonadotrophin (eCG) in the official product information. These terms refer to the same hormone used in veterinary reproductive management.

Q: Is a veterinary prescription required to purchase Folligon?

Yes, Folligon is classified as a Veterinary Medicinal Product subject to veterinary prescription by regulatory authorities. This indicates the product must be obtained with a veterinary prescription.

Q: How soon after administration does Folligon take effect?

Studies and official information indicate that Folligon is rapidly absorbed into the body from the injection site. Its biological effect is prolonged due to a very long half-life, meaning that a single injection can support the required ovarian stimulation over several days.

Q: What is the withdrawal period for meat and milk after Folligon use?

Regulatory documents explicitly state that the official withdrawal period for both Meat and offal and Milk in all target species (cattle, sheep, and pig) is zero days.

Q: What is the shelf life of the freeze-dried Folligon product?

The official shelf life for the freeze-dried powder in its original packaging is 3 years. Once the product is mixed with the solvent for reconstitution, the prepared solution is stable for 24 hours, provided it is kept refrigerated.

How to Store and Dispose of Folligon?

Regulatory documentation defines specific, mandatory conditions for the storage and handling of Folligon (Pregnant Mare Serum Gonadotrophin).

Storage Requirements

Handling and Disposal

Care must be taken to avoid accidental self-injection. In case of accidental spillage on the skin, the area should be washed immediately with soap and water. Disposal of unused product or waste materials must not occur via wastewater or household trash. Instead, disposal must be carried out according to the local and national requirements for unused medicinal products.